Nurix Therapeutics is a biotech company developing targeted protein modulation drugs.
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels.
Nurix Therapeutics was founded in 2012 by John Kuriyan, Michael Rapé, and Arthur Weiss. The company is headquartered in San Francisco, California.
Nurix develops novel therapies that modulate protein levels through small molecule drugs targeting E3 ligases. Nurix’s pipeline is focused on developing drugs for immune-mediated diseases and hematologic cancers including immuno-oncology therapeutics.
Nurix recently formed two new strategic collaborations with Sanofi and Gilead to develop novel protein degradation therapies in multiple therapeutic areas. Together, these collaborations provided Nurix with $100 million in upfront payments and the potential for over $4.5 billion in milestones with additional royalties and certain co-development options.
Nurix is backed by Foresite Capital, Bain Capital Life Sciences, The Column Group, Third Rock Ventures, Boxer Capital (Tavistock Group), EcoR1 Capital and others. The company raised $120M in an oversubscribed financing on Mar 12, 2020. This brings Nurix's total funding to $165.2M to date.